875339-10-9Relevant academic research and scientific papers
Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases
Claridge, Stephen,Raeppel, Franck,Granger, Marie-Claude,Bernstein, Naomy,Saavedra, Oscar,Zhan, Lijie,Llewellyn, David,Wahhab, Amal,Deziel, Robert,Rahil, Jubrail,Beaulieu, Normand,Nguyen, Hannah,Dupont, Isabelle,Barsalou, Annie,Beaulieu, Carole,Chute, Ian,Gravel, Serge,Robert, Marie-France,Lefebvre, Sylvain,Dubay, Marja,Pascal, Roussen,Gillespie, Jeff,Jin, Zhiyun,Wang, James,Besterman, Jeffrey M.,MacLeod, A. Robert,Vaisburg, Arkadii
, p. 2793 - 2798 (2008/12/21)
A series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases is described. The compounds demonstrated potency with IC50 values in the low nanomolar range in vitro while the lead compound also showed in vivo activity against various human tumor xenograft models in mice. Further exploration of this class of compounds is underway.
INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING
-
Page/Page column 60-61, (2010/02/15)
The invention relates to the inhibition of vascular endothelial growth factor (VEGF) receptor signaling and hepatocyte growth factor (HGF) receptor signaling. The invention provides compounds and methods for inhibiting VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions
